European Union - Icelandic - EMA (European Medicines Agency)

sandoz gmbh - epóetín alfa - anemia; kidney failure, chronic - sýklalyf - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjarta stöðu, fyrirfram núverandi blóðleysi á að byrja í lyfjameðferð).

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 5 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - hydroxocobalaminum hýdróklóríð - stungulyf, lausn - 1 mg/ml

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s* - acetylcysteinum inn - freyðitafla - 600 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 300 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz gmbh* - rifampicinum inn - hart hylki - 150 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 0,5 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 1 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 2 mg

Iceland - Icelandic - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - tacrolimusum mónohýdrat - hart forðahylki - 3 mg